Population Pharmacokinetics of Nevirapine, Zidovudine, and Didanosine in Human Immunodeficiency Virus-Infected Patients
暂无分享,去创建一个
Lewis B. Sheiner | Martin S. Hirsch | Victoria A. Johnson | Michael D. Hughes | M. Hughes | M. Hirsch | V. Johnson | R. D’Aquila | L. Sheiner | M. Fischl | M. Myers | J. Sommadossi | Jean-Pierre Sommadossi | R. D'Aquila | Margaret A. Fischl | Richard T. D’Aquila | Xiao-Jian Zhou | Maureen Myers | Xiao-jian Zhou | M. Hirsch | Xiao-jian Zhou
[1] T. Greenough,et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. , 1995, The Journal of infectious diseases.
[2] J L Sullivan,et al. Pharmacokinetics of nevirapine: initial single-rising-dose study in humans , 1993, Antimicrobial Agents and Chemotherapy.
[3] Relationship between body weight, body surface area and serum zidovudine pharmacokinetic parameters in adult, male HIV‐infected patients , 1994, AIDS.
[4] S D Kemp,et al. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. , 1995, Science.
[5] M. Hirsch,et al. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy , 1993, Nature.
[6] E. De Clercq,et al. Non‐nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV‐1) infections: Strategies to overcome drug resistance development , 1996, Medicinal research reviews.
[7] M A Fischl,et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. , 1987, The New England journal of medicine.
[8] M. Niu,et al. Nevirapine, Zidovudine, and Didanosine Compared with Zidovudine and Didanosine in Patients with HIV-1 Infection , 1996, Annals of Internal Medicine.
[9] J. Sommadossi. Nucleoside analogs: similarities and differences. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] J. Cameron,et al. Selection in vitro of an HIV-1 variant resistant to both lamivudine (3TC) and zidovudine. , 1996, AIDS.
[11] H. Balfour,et al. Comparative Pharmacokinetics of Zidovudine in Healthy Volunteers and in Patients With AIDS With and Without Hepatic Disease , 1992, Pharmacotherapy.
[12] A. Lazzarin,et al. Pharmacokinetics of Zidovudine in HIV‐Positive Patients with Liver Disease , 1994, Journal of clinical pharmacology.
[13] J. Darbyshire,et al. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals , 1996, The Lancet.
[14] J. Lambert,et al. Impact of bioavailability on determination of the maximal tolerated dose of 2',3'-dideoxyinosine in phase I trials , 1992, Antimicrobial Agents and Chemotherapy.
[15] J W Mulder,et al. Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group. , 1996, The Journal of infectious diseases.
[16] M A Fischl,et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. , 1987, The New England journal of medicine.
[17] S. Broder,et al. Pharmacokinetics of 2′, 3′‐dideoxyadenosine and 2′, 3′‐dideoxyinosine in patients with severe human immunodeficiency virus infection , 1990, Clinical pharmacology and therapeutics.
[18] M. Hirsch,et al. Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro. , 1996, The Journal of infectious diseases.
[19] R. Diasio,et al. Clinical pharmacokinetics of 3′‐azido‐3′‐deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite, 3′‐amino‐3′‐deoxythymidine , 1992, Clinical pharmacology and therapeutics.
[20] P. Harrigan,et al. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients : A randomized controlled comparison with zidovudine monotherapy , 1996 .
[21] D. Kuritzkes,et al. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients , 1996, AIDS.
[22] A. Nitenberg,et al. Reversibility by dipyridamole of thallium-201 myocardial scan defects in patients with sarcoidosis. , 1988, The American journal of medicine.
[23] S. Liao,et al. Pharmacokinetics and bioavailability of zidovudine in humans. , 1988, The American journal of medicine.
[24] Harold C. Standiford,et al. Population pharmacokinetics of zidovudine , 1990 .
[25] J. Sommadossi,et al. Comparative pharmacokinetics of zidovudine and its toxic catabolite 3'-amino-3'-deoxythymidine in HIV-infected patients. , 1996 .
[26] J. Beijnen,et al. Pharmacokinetic variability of zidovudine in HIV‐infected individuals: subgroup analysis and drug interactions , 1994, AIDS.
[27] J. Kahn,et al. HIV-1 protease inhibitors. A review for clinicians. , 1997 .
[28] M. Beltangady,et al. Analysis of potential risk factors associated with the development of pancreatitis in phase I patients with AIDS or AIDS-related complex receiving didanosine. , 1994, The Journal of infectious diseases.
[29] F. Valentine,et al. Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome—related complex , 1991, Clinical pharmacology and therapeutics.
[30] S. Broder,et al. Plasma and cerebrospinal fluid pharmacokinetics of 3′‐azido‐3′‐deoxythymidine: A Novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases , 1987, Clinical pharmacology and therapeutics.
[31] F. Valentine,et al. Population Pharmacokinetic Analysis of Didanosine (2′,3′‐Dideoxyinosine) Plasma Concentrations Obtained in Phase I Clinical Trials in Patients with AIDS or AIDS‐Related Complex , 1992, Journal of clinical pharmacology.
[32] C. Nielsen,et al. Development of resistance to zidovudine (ZDV) and didanosine (ddl) in HIV from patients in ZDV, ddl and alternating ZDV/ddl therapy , 1996, AIDS.
[33] L. Sheiner,et al. Population pharmacokinetics of didanosine in patients with human immunodeficiency virus infection. , 1996, The Journal of infectious diseases.
[34] M. Dudley. Clinical pharmacokinetics of nucleoside antiretroviral agents. , 1995, The Journal of infectious diseases.